Profiling of microRNAs by next-generation sequencing: Potential biomarkers for diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Diffuse large B cell lymphoma (DLBCL) is a prevalent non-Hodgkin lymphoma.
• Non-coding microRNAs (miRNAs) significantly influence gene expression and can act as oncogenes or tumor suppressors in DLBCL.
• Understanding miRNA roles is crucial for DLBCL progression and treatment.

Purpose of the Study:

• To investigate the roles of microRNAs (miRNAs) in patients with DLBCL.
• To identify potential diagnostic or prognostic biomarkers for DLBCL using miRNA profiling.
• To explore altered genes and miRNAs as potential therapeutic targets.

Main Methods:

• The study analyzed miRNA expression in formalin-fixed, paraffin-embedded (FFPE) tissues from seven DLBCL patients and three healthy controls.
• Next-generation sequencing (NGS) was employed for sensitive and accurate miRNA profiling.
• MiRNA was extracted from existing FFPE tissue specimens for analysis.

Main Results:

• Distinct microRNA (miRNA) expression profiles were observed between DLBCL patients and healthy controls.
• Specific miRNAs, including hsa-mir-877-3p, hsa-mir-1291, and hsa-mir-181a-5p, were found to target multiple genes.
• The study identified expression of various hsa-mir miRNAs in patient samples.

Conclusions:

• MicroRNA (miRNA) profiling of FFPE tissues can differentiate DLBCL patients from controls.
• MiRNA levels may serve as valuable prognostic or diagnostic biomarkers for DLBCL.
• Altered miRNAs and their target genes represent potential avenues for novel DLBCL therapies.